Mating system and population genetic structure of the bulldog ant Myrmecia pavida

Understanding the evolution of the alternative mating strategies of monandry and polyandry is a fundamental problem in evolutionary biology because of the cost-benefit trade-offs associated with mating for females. The problem is particularly intriguing in the social insects because queens in most species appear to be obligately monandrous (i.e., only a single male fathers their offspring), while those in a minority of species have evolved high, and sometimes extreme, polyandry. One group which may shed particular insight is the ant subfamily Myrmeciinae (Myrmecia and Nothomyrmecia). Here we examine the population and colony genetic structure of the bulldog ant Myrmecia pavida CLARK, 1951 by genotyping offspring workers from 45 colonies. We find little evidence of geographic structuring or inbreeding in the population, indicating that the species outbreeds, most probably in mating swarms. We also find that queens of M pavida show moderately high polyandry, with 84% having mated with between two and seven males, and an overall mean observed mating frequency of 3.8. This is significantly higher than previously reported for queens of Nothomyrmecia macrops, in which most females mate singly. This was similar to that of M pyriformis, M brevinoda, and M pilosula, the three congenerics for which mating frequencies have recently been reported. The two genera in the Myrmeciinae therefore appear to show multiple transitions in mating frequency and further investigation of the subfamily may be highly informative for disentangling the forces driving the evolution of alternative mating strategies

Examining the policy-practice gap: the divergence between regulation and reality in organic fertiliser allocation in pasture based systems

Slurry and animal manure generated from livestock production systems are typically recycled back to land to replace nutrients removed in products leaving the farm such as milk, meat and grass. Avoiding environmental losses of nutrients due to slurry spreading requires careful management, contingent on farmers following agronomic advice and policy regulation, yet, nutrient losses to water from agriculture continues to put a significant pressure on water quality. The objective of this study was to examine whether a policy-practice gap in slurry management exists on farms by identifying the factors that influence the decision to spread slurry, across the farm. To achieve this, a Heckman selection model was used to identify the drivers of slurry management using farm and field management records and soil information from commercial livestock farms combined with spatial datasets on landscape position. The main drivers influencing the decision to spread slurry were practical considerations relating to the structure and spatial arrangement of fields on the farm, such as proximity to farm yard, as well as landscape position. Field and landscape variables were also related such as slope, elevation, drainage capacity, soil type, presence of open ditches, and soil phosphorus (P) level. Fields with excessive soil P content had a high probability of receiving slurry in greater amounts, thus challenging the assumption that farmers use soil testing to guide slurry management, and identifying the main agri-environmental policy-practice gap and a need for better knowledge exchange in this area. Despite current policy, practical considerations override soil testing and these results showed that slurry management and allocation is rooted in the spatial arrangement of fields on the farm. The results indicated that farmer decisions are driven by factors that relate to the time, cost and labour involved in spreading slurry, indicating the need for water quality measures and policy to consider the practical constraints and considerations from the viewpoint of the farm

Statement of the Third International Exercise-Associated Hyponatremia Consensus Development Conference, Carlsbad, California, 2015

The third International Exercise-Associated Hyponatremia (EAH) Consensus Development Conference convened in Carlsbad, California in February 2015 with a panel of 17 international experts. The delegates represented 4 countries and 9 medical and scientific sub-specialties pertaining to athletic training, exercise physiology, sports medicine, water/sodium metabolism, and body fluid homeostasis. The primary goal of the panel was to review the existing data on EAH and update the 2008 Consensus Statement.1 This document serves to replace the second International EAH Consensus Development Conference Statement and launch an educational campaign designed to address the morbidity and mortality associated with a preventable and treatable fluid imbalance. The following statement is a summary of the data synthesized by the 2015 EAH Consensus Panel and represents an evolution of the most current knowledge on EAH. This document will summarize the most current information on the prevalence, etiology, diagnosis, treatment and prevention of EAH for medical personnel, athletes, athletic trainers, and the greater public. The EAH Consensus Panel strove to clearly articulate what we agreed upon, did not agree upon, and did not know, including minority viewpoints that were supported by clinical experience and experimental data. Further updates will be necessary to both: (1) remain current with our understanding and (2) critically assess the effectiveness of our present recommendations. Suggestions for future research and educational strategies to reduce the incidence and prevalence of EAH are provided at the end of the document as well as areas of controversy that remain in this topic. [excerpt

Malaria chemoprophylaxis and the serologic response to measles and diphtheria-tetanus-whole-cell pertussis vaccines

BACKGROUND: Acute malaria has been associated with a decreased antibody response to tetanus and diphtheria toxoids, meningococcal, salmonella, and Hib vaccines. Interest in giving malaria drug therapy and prevention at the time of childhood immunizations has increased greatly following recent trials of intermittent preventive therapy during infancy (IPTi), stimulating this re-analysis of unpublished data. The effect of malaria chemoprophylaxis on vaccine response was studied following administration of measles vaccines and diphtheria-tetanus-whole cell pertussis (DTP) vaccines. METHODS: In 1975, six villages divided into two groups of children ≤74 months of age from Burkina Faso, were assigned to receive amodiaquine hydrochloride chemoprophylaxis (CH+) every two weeks for seven months or no chemoprophylaxis (CH-). After five months, children in each group received either one dose of measles or two doses of DTP vaccines. RESULTS: For recipients of the measles vaccine, the seroconversion rates in CH+ and CH- children, respectively, were 93% and 96% (P > 0.05). The seroresponse rates in CH+ and CH- children respectively, were 73% and 86% for diphtheria (P > 0.05) and 77% and 91% for tetanus toxoid (P > 0.05). In a subset analysis, in which only children who strictly adhered to chemoprophylaxis criteria were included, there were, likewise, no significant differences in seroconversion or seroresponse for measles, diphtheria, or tetanus vaccines (P > 0.05). While analysis for pertussis showed a 43% (CH+) and 67% (CH-) response (P < 0.05), analyses using logistic regression to control for sex, age, chemoprophylaxis, weight-for-height Z-score, and pre-vaccination geometric mean titer (GMT), demonstrated that chemoprophylaxis was not associated with a significantly different conversion rate following DTP and measles vaccines. Seven months of chemoprophylaxis decreased significantly the malaria IFA and ELISA GMTs in the CH+ group. CONCLUSION: Malaria chemoprophylaxis prior to vaccination in malaria endemic settings did not improve or impair immunogenicity of DTP and measles vaccines. This is the first human study to look at the association between malaria chemoprophylaxis and the serologic response to whole-cell pertussis vaccine

Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia

PURPOSE: In X-linked hypophosphatemia (XLH), excess fibroblast growth factor-23 causes hypophosphatemia and low calcitriol, leading to musculoskeletal disease with clinical consequences. XLH treatment options include conventional oral phosphate with active vitamin D, or monotherapy with burosumab, a monoclonal antibody approved to treat children and adults with XLH. We have previously reported outcomes up to 64 weeks, and here we report safety and efficacy follow-up results up to 160 weeks from an open-label, multicenter, randomized, dose-finding trial of burosumab for 5- to 12-year-old children with XLH. METHODS: After 1 week of conventional therapy washout, patients were randomized 1:1 to burosumab every 2 weeks (Q2W) or every 4 weeks (Q4W) for 64 weeks, with dosing titrated based on fasting serum phosphorus levels between baseline and week 16. From week 66 to week 160, all patients received Q2W burosumab. RESULTS: Twenty-six children were randomized initially into each Q2W and Q4W group and all completed treatment to week 160. In 41 children with open distal femoral and proximal tibial growth plates (from both treatment groups), total Rickets Severity Score significantly decreased by 0.9 ± 0.1 (least squares mean ± SE; P < 0.0001) from baseline to week 160. Fasting serum phosphorus increases were sustained by burosumab therapy throughout the study, with an overall population mean (SD) of 3.35 (0.39) mg/dL, within the pediatric normal range (3.2-6.1 mg/dL) at week 160 (mean change from baseline P < 0.0001). Most adverse events were mild to moderate in severity. MAIN CONCLUSIONS: In children with XLH, burosumab administration for 160 weeks improved phosphate homeostasis and rickets and was well-tolerated. Long-term safety was consistent with the reported safety profile of burosumab. CLINICALTRIALS.GOV: NCT0216357